-+ 0.00%
-+ 0.00%
-+ 0.00%

OCULAR THERAPEUTIX: COMPLEMENTARY SOL-R PHASE 3 NON-INFERIORITY TRIAL OF AXPAXLI IN WET AMD TO CONTINUE AS PLANNED, TOPLINE DATA EXPECTED Q1 2027

Reuters·02/17/2026 12:00:06

Please log in to view news